



Medicine: lusutrombopag (brand name: Mulpleo®) for thrombocytopenia

Shionogi Limited

What is lusutrombopag for?

Lusutrombopag is used to prevent excessive bleeding in adults with thrombocytopenia that is caused by chronic liver disease. Patients with thrombocytopenia have a reduced number of platelets, which are a component of blood that help it to clot. Lusutrombopag is for treating patients who have severe thrombocytopenia due to chronic liver disease and who are having an invasive procedure (e.g. a surgical or diagnostic procedure that involves cutting the skin).

How does lusutrombopag work?

Platelets are made in the bone marrow. Lusutrombopag stimulates the bone marrow to produce more platelets, helping to increase the number of platelets in the bloodstream which helps the blood to clot.

What has SMC said?

SMC has accepted lusutrombopag for the treatment of severe thrombocytopenia in adults with chronic liver disease as described above.



Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration of the evidence, SMC was able to accept lusutrombopag as a possible treatment within NHSScotland.

What does SMC's decision mean for me?

If your healthcare professional thinks that lusutrombopag for use as described above is the right medicine for you, you should be able to have your treatment on the NHS in Scotland. For further information see:

Medicines in Scotland: What's the right treatment for me?

www.healthcareimprovementscotland.org/medicinesbooklet.aspx



More information

The organisations below can provide more information and support for people with liver disease and their families. SMC is not responsible for the content of any information provided by external organisations.

British Liver Trust



<https://britishlivertrust.org.uk/>



0800 652 7330

The PBC Foundation



<https://www.pbcfoundation.org.uk/>



0131 556 6811

You can find out more about lusutrombopag in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>

Date advice published: 9 December 2019

SMC No: (SMC2227)